The Relative Strength Index forecast reference data for Neuropace is based on the equity's recent trading history. This page summarizes the model output and key accuracy metrics for reference.
All Relative Strength Index forecast figures shown for Neuropace are reference data reflecting model output based on available historical prices.
Relative Strength Index Analysis Today
Neuropace has current Relative Strength Index of 0.
On March 20 2026 Neuropace was traded for 13.00 at the closing time. The top price for the day was 13.23 and the lowest listed price was 12.68 . The trading volume for the day was 301.9 K. The trading history from March 20, 2026 did not cause price change. The trading delta at closing time against the current closing price is 0.15% .
Whether a novice or experienced investor, anyone considering Neuropace needs to understand the dynamics of Neuropace's price movement. Price charts for Neuropace Stock contain a significant amount of noise that can distort investment decisions.
The following equities are related to Neuropace within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Neuropace against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
Analyzing market strength indicators for Neuropace enables investors to understand how the stock performs relative to overall market momentum. These indicators are valuable tools for identifying when to enter or exit positions in Neuropace.
Identifying and analyzing Neuropace's key risk indicators is a foundational step in projecting how its price may evolve. This process quantifies the risk associated with Neuropace's and decide how to manage it.
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Neuropace
Story coverage around Neuropace often expands when market conditions, narrative momentum, or risk-adjusted performance make the security more visible to investors. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
A short-interest review of Neuropace provides context for understanding whether skepticism in the market is becoming more influential. The stronger read compares short sentiment with trend behavior, volume, and the broader market narrative.
Common Stock Shares Outstanding
32.7 M
Cash And Short Term Investments
61.1 M
More Resources for Neuropace Stock Analysis
Initial analysis of Neuropace centers on its financial statements and observed trends. Ratios connect earnings, costs, and operational efficiency. These metrics are based on Neuropace's reported financial results. Supporting reports for Neuropace Stock are presented below:
